Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

48.27 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Supernus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Supernus Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript ↗
Supernus Pharmaceuticals (NASDAQ:SUPN) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs.... 
Via Benzinga
Topics Earnings
News headline image
3 Russell 2000 Stocks We Approach with Caution
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ... 
Via StockStory
News headline image
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Why Supernus Pharmaceuticals Stock Topped the Market Today ↗
It's effecting a "merger of equals" with a peer. 
Via The Motley Fool
News headline image
Halper Sadeh LLC is Investigating Whether SUPN, ITGR, BOW are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Supernus Pharmaceuticals Q2 Earnings Call Highlights ↗
Supernus Pharmaceuticals (NASDAQ:SUPN) and Indivior Pharmaceuticals announced a proposed all-stock, tax-free merger of equals that would create a central nervous system-focused biopharmaceutical... 
Via MarketBeat
Topics Earnings
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
Supernus Pharmaceuticals (NASDAQ:SUPN) Surprises With Q2 CY2026 Sales, Stock Jumps 24.9%
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 3... 
Via StockStory
News headline image
Supernus Announces Second Quarter 2026 Financial Results
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
From Supernus Pharmaceuticals, Inc.; Indivior Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Supernus Pharmaceuticals Earnings: What To Look For From SUPN
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be reporting results this Tuesday after market hours. Here’s what to look for. S... 
Via StockStory
Topics Artificial Intelligence
News headline image
Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
1 Cash-Producing Stock on Our Buy List and 2 That Underwhelm
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
News headline image
1 Growth Stock to Stash and 2 We Turn Down
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr... 
Via StockStory
Topics Artificial Intelligence
News headline image
Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Branded Pharmaceuticals Stocks Q1 Teardown: Supernus Pharmaceuticals (NASDAQ:SUPN) Vs The Rest
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, incl... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 of Wall Street’s Favorite Stocks We Approach with Caution
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
Via StockStory
News headline image
3 Reasons to Avoid SUPN and 1 Stock to Buy Instead
Over the last six months, Supernus Pharmaceuticals’s shares have sunk to $43.79, producing a disappointing 9.4% loss - a stark contrast to the S&P 500’s 9.3%... 
Via StockStory
Topics Stocks Supply Chain
News headline image
1 Cash-Heavy Stock on Our Watchlist and 2 Facing Challenges
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg... 
Via StockStory
News headline image
Supernus Pharmaceuticals to Participate in June Investor Conferences
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
3 Stocks Under $50 with Open Questions
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However... 
Via StockStory
News headline image
3 Small-Cap Stocks That Concern Us
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Growth Stocks We Approach with Caution
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr... 
Via StockStory
News headline image
What to Know About This Fund’s Sale of a Pharma Stock Up 56% in a Year ↗
Supernus Pharmaceuticals delivers specialty therapies for CNS disorders, targeting healthcare providers and specialty pharmacies nationwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
5 Revealing Analyst Questions From Supernus Pharmaceuticals’s Q1 Earnings Call
Supernus Pharmaceuticals’ first quarter saw a positive market response, as management attributed the revenue growth to robust demand for its key growth produ... 
Via StockStory
Topics Earnings Supply Chain
News headline image
Why Supernus Pharmaceuticals (SUPN) Stock Is Up Today
What Happened? Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) jumped 6.8% in the afternoon session after the company repor... 
Via StockStory
Topics Earnings Economy
News headline image
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
From Supernus Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
SUPN Q1 Deep Dive: Growth Products Drive Revenue Upside, Guidance Highlights Execution Challenges
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 38.6% year on yea... 
Via StockStory
Topics Economy Supply Chain
News headline image
1 Healthcare Stock with Competitive Advantages and 2 Facing Challenges
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.